|
biomedicina slovenica |
pr=Čufer : 401-500
-
Kragelj Borut; Sedmak Boris; Borštner Simona; Čufer Tanja
Vloga obsevanja pri zdravljenju lokaliziranega raka sečnika
2004 ►
-
Čufer Tanja
Clinical utility of serine proteases in breast cancer
[Klinična uporabnost serinskih proteaz pri raku dojk]
2004 ►
-
Sonc M; Omerza M; Čufer T; Slanc J; Kozjek F
Pharmacoeconomics of salvage therapy and quality of life in metastatic breast cancer patients
2003 ►
-
Atalay G; Biganzoli L; Renard F; Paridaens R; Čufer T; Coleman R; Calvert AH; Gamucci T; Minisini A; Therasse P
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
2003 ►
-
Čufer Tanja
Clinical utility of serine proteases in breast cancer
2004 ►
-
Čufer Tanja
Rak dojke
2003 ►
-
Čufer Tanja
Imenitna pobuda
2003 ►
-
Čufer Tanja
Dopolnilno sistemsko zdravljenje raka dojk
[Adjuvant systemic treatment of breast cancer]
2003 ►
-
Spataro Vito J; Lamovec J; Jančar J; Nowak J; Eržen D; Naglas M; Senčar M; Červak J; Cerar O; Štabuc B; Šebek S; Čufer T
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International breast study group trial 5
2003 ►
-
Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
2003 ►
-
Paridaens R; Dirix L; Beex L; Nooij MN; Čufer T; Lohrisch C; Biganzoli L; van Hoorebeeck I; Duchateau L; Lobelle JP; Piccart M
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control
2000 ►
-
Maillet P; Bonnefoi H; Vaudan-Vutskits G; Pajk B; Čufer T; Foulkes WD; Chappuis PO; Sappino AP
Constitutional alterations of the ATM gene in early onset sporadic breast cancer
2002 ►
-
Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
2003 ►
-
Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Schaefer P; Atalay G; Piccart M
An EORTC phase I study of capecitabine (xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
2003 ►
-
Čufer Tanja; Pajk Bojana
Sistemska terapija rakave bolezni in njen vpliv na bolnika
2002 ►
-
Čufer T; Borštnar S; Vrhovec I
Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer
2003 ►
-
Čufer Tanja
Osnovni principi zdravljenja raka
2002 ►
-
Čufer Tanja
Palliative and supportive care
2003 ►
-
Borštnar Simona; Vrhovec Ivan; Čufer Tanja
Urokinazni aktivator plazminogena, njegovi zaviralci in receptor pri raku dojke - novi napovedni dejavniki poteka bolezni in odgovora na sistemsko zdravljenje
2003 ►
-
Škrbinc B; Babič A; Čufer T; Us-Krašovec M
Cytological grading of breast cancer in Giemsa-stained fine needle aspiration smears
2001 ►
-
Pompe-Kirn Vera; Zakotnik Branko; Zadnik Vesna; Anžič Jožica; Auersperg Marija; Budihna Marjan; Cerar Olga; Čufer Tanja; Debeljak Andrej; Eržen Janez; Fras Peter; Hočevar Marko; Jezeršek-Novakovič Barbara; Jančar Boris; Kmetec Andrej; Kragelj Borut; Lindtner Jurij; Majdič Elga; Markovič Saša; Marolt France; Ocvirk Janja; Pretnar Jože; Repše Stane; Rudolf Zvonimir; Sedmak Boris; Sok Miha; Stanovnik Marjeta; Šmid Lojze; Štabuc Borut; Tomšič Radka; Vovk Marjeta; Uršič-Vrščaj Marjetka; Zwitter Matjaž; Žumer-Pregelj Mirjana
Preživetje bolnikov z rakom v Sloveniji: 1983-1997
[Cancer patients survival in Slovenia: 1983-1997]
2003 ►
-
Biganzoli Laura; Čufer Tanja; Bruning Peter; Coleman Robert E; Duchateau Luc; Rapoport Bernardo; Nooij Marianne; Delhaye Francois; Miles D; Sulkes Aaron
Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
2003 ►
-
Lahajnar-Čavlovič Slavica; Švab Igor; Čufer Tanja; Krčevski-Škvarč Nevenka; Manohin Aleksander; Kersnik Janko; Ažman Drago; Velepič Marina; Logonder Mira; Sonc Monika; Berložnik Magda; Pentek Metka; Vodopivec-Jamšek Vlasta; Tomazin Iztok
Priporočila za zdravljenje bolečine pri odraslem bolniku z rakom
2001 ►
-
Čufer Tanja
Izguba telesne teže in podhranjenost bolnikov z rakom
2002 ►
-
Bergant Damijan; Hočevar Marko; Čufer Tanja
Karcinom Merklovih celic
2002 ►
-
Čufer Tanja
Odmev na članek o delu razsodišča II. stopnje
2003 ►
-
Čufer Tanja; Golouh Rastko; Noč Gorazd; Rudolf Zvonimir; Snoj Marko; Vardijan Rudolf
Obračun na onkologiji
2002 ►
-
Čufer T
Symptomatic and supportive care in metastatic disease
2002 ►
-
Borštnar S; Vrhovec I; Čufer T
Prognostic value of plasminogen activator inhibitors in breast cancer
2002 ►
-
Awada A; Biganzoli L; Čufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
2002 ►
-
Biganzoli L; Čufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trial
2002 ►
-
Borštnar S; Vrhovec I; Svetič B; Čufer T
Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients
2002 ►
-
Čufer Tanja
Rak dojke
2001 ►
-
Biganzoli L; Bonnefoi H; Mauriac L; Čufer T; Kabanga-Ngalula E; Hebert D; Piccart M
Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: a safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study
2001 ►
-
Žgajnar J; Hočevar M; Bešić N; Vrščaj M; Pajk B; Čufer T; Jakopin C; Krajc M
Genetic counceling for hereditary breast and ovarian cancer. Our experience at the Institute of oncology in Ljubljana, Slovenija
2002 ►
-
Jagodic M; Vrhovec I; Borštnar S; Matos E; Čufer T
Prognostic value of different proteolitic factors in primary breast cancer
2002 ►
-
Matos E; Vrhovec I; Borštnar S; Jagodic M; Čufer T
Predictive value of PAI-1 and PAI-2 in breast cancer
2002 ►
-
Pajk B; Borštnar S; Vrhovec I; Čufer T
PAI-1 is independant prognostic factor in the elderly breast cancer patients
2002 ►
-
Čufer Tanja
Nosečnost in rak dojk
2001 ►
-
Žgajnar J; Hočevar M; Bešič N; Čufer T; Pajk B; Jakopin C; Vrščaj M; Krajc M
Genetsko svetovanje za dedni rak dojk in jajčnikov. Izkušnje Onkološkega inštituta v Ljubljani
2002 ►
-
Štotl J; Čufer T; Kozjek F; Sonc M
Comparison of quality of lif of breast cancer patients, treated with two diferent chemotherapeutic schemes
2002 ►
-
Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
2001 ►
-
Look Maxime P; van Putten Wim LJ; Duffy Michael J; Harbeck Nadia; Christensen Ib Jarle; Thomsen Christoph; Kates Ronald; Spyratos Frederique; Fernoe Marten; Čufer Tanja; Borštnar Simona
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
2002 ►
-
Čufer T; Vrhovec I; Borštnar S
Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival
2002 ►
-
Svetic B; Vrhovec I; Kramberger M; Borštnar S; Čufer T
The influence of different buffers on tumor tissue preparation for biochemical determination of cathepsins D and L
2002 ►
-
Thuerlimann B; Price KN; Castiglione M; Lindtner J; Eržen D; Čufer T; Červek J; Cerar O; Zakotnik B; Majdič E; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International breast cancer study group trial 11-93
2001 ►
-
Bračko Matej; Us-Krašovec Marija; Čufer Tanja; Lamovec Janez; Zidar Andreja; Goehde Wolfgang
Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma
2001 ►
-
Bonetti M; Gelber RD; Goldhirsch A; Lindtner J; Eržen D; Majdič E; Štabuc B; Plesničar A; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M; Cerar O; Šebek S; Novak J; Naglas M; Senčar M; Červek J; Čufer T
Features that predict responsiveness to chemotherapy and endocrine therapies
2001 ►
-
Čufer Tanja
Dopolnilno zdravljenje
2001 ►
-
Dirix L; Piccart MJ; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European orgnisation for the research and treatment of cancer (EORTC breast group) phase II trial with Pharmacia and Upjohn
2001 ►
-
Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Yague C; Hebert D; Piccart M
An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced / inflammatory (LA/I) or large operable (LO) breast cancer (BC)
2001 ►
-
Borštnar S; Vrhovec I; Čufer T
Prognostic value of PAI-1 and PAI-2 combination in primary breast cancer
2001 ►
-
Lohrisch C; Paridaens R; Dirix LY; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
Adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European organization of research and treatment of cancer (Breast group) trial with Pharmacias' Upjohn
2001 ►
-
Čufer Tanja
Spoštovani urednik!
2001 ►
-
Čufer Tanja
Nova zdravila za zdravljenje raka
2001 ►
-
Čufer Tanja
Za pravilen nadzor in oskrbo bolnikov ni dovolj le dobra volja...: kako bolje zdraviti raka z zdravili
2001 ►
-
Čufer Tanja
Kaj lahko o raku izvemo na internetu?
2001 ►
-
Čufer Tanja
Nova biološka zdravila za raka
2001 ►
-
Jagodic Monika; Čufer Tanja; Zakotnik Branko; Červek Jožica
Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients
2001 ►
-
Zwitter M; Čufer T; Wein W
Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer
2001 ►
-
Čufer Tanja; Us-Krašovec Marija
Pomen pretočnocitometrične analize DNA pri načrtovanju zdravljenja karcinoma dojke
2001 ►
-
Awada A; Nooij M; Biganzoli L; Čufer T; Beek L; Batter V; Piccart MJ
A phase I study of continuous infusion 5-fluorouracil (F-intu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline- (A) refractory or A- and taxane- (T) pretreated metastatic breast cancer (MBC)
2000 ►
-
Biganzoli L; Čufer T; Fargeot P; Rapoport B; Nooij M; Duchateau L; van Hoorebeeck I; Yague C; Epelbaum R; Piccart M
Doxorubicin (A)/taxol (T): a safe regimen in terms of cardiac toxicity in the contex of an EORTC multicenter trial
2000 ►
-
Biganzoli L; Čufer T; Bruning P; Coleman R; Calvert H; Gamucci T; Twelves C; di Paola E Donato; Duchateau L; Yague C
Doxorubicin (A) / Taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metasttaic breast cancer (MBC): a phase III study
2000 ►
-
Čufer Tanja
Sistemsko zdravljenje raka
2000 ►
-
Čufer Tanja
Celovita obravnava raka dojke
2000 ►
-
Čufer Tanja
Rak dojke ni ena bolezen
2001 ►
-
Jagodic M; Zakotnik B; Golouh R; Červek J; Čufer T
Response to oral etoposide in advanced breast cancer: correlation with expression of c-erbB-2 protein
2000 ►
-
Borštnar Simona; Vrhovec I; Čufer Tanja
Prognostic value of urokinase plasminogen activator inhibitors in cytosols from breast cancer patients
2000 ►
-
Pajk Bojana; Čufer Tanja; Borštnar Simona; Zakotnik Branko; Us-Krašovec Marija
Predictive value of DNA ploidy in elderly breast cancer patients treated with tamoxifen
2000 ►
-
Čufer Tanja
Update on breast cancer chemotherapy
2000 ►
-
Čufer Tanja; Pfeifer Marija; Vrhovec Ivan; Frangež Robert; Kosec Marjan; Mrhar Aleš; Grabnar Iztok; Golouh Rastko; Vogrinc Sonja; Sikič Branimir Ivan
Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin
2000 ►
-
Prechtl A; Harbeck N; Thomssen C; Meisner C; Braun M; Untch M; Wieland M; Lisboa B; Čufer T; Graeff H
Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
2000 ►
-
Čufer T; Bračko M
Myeloid metaplasia of the breast
2001 ►
-
Serša Gregor; Čufer Tanja; Čemažar Maja; Reberšek Martina; Rudolf Zvonimir
Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review
2000 ►
-
Reberšek Martina; Čufer Tanja; Rudolf Zvonimir; Serša Gregor
Electrochemotherapy with cisplatin of breast cancer tumour nodules in male patient
2000 ►
-
Čufer Tanja
Ali pomeni ohranitev organov tudi boljšo kakovost življenja? Pogovor s prof. dr. Ianom Tannockom
2000 ►
-
Reberšek Martina; Čufer Tanja; Rudolf Zvonimir; Serša Gregor
Electrochemotherapy with cisplatin of breast cancer tumor modules in a male patient
[Elektrokemoterapija s cisplatinom pri bolniku z rakom dojke]
2000 ►
-
Čufer T
Adjuvant therapy of breast cancer: update
1999 ►
-
Kozjek F; Sonc M; Čufer T; Primožič S
Drug-drug interactions and pseudo double medications in the treatment of oncological patients
2000 ►
-
Matos Tadeja; Čufer Tanja; Červek Jožica; Borštnar Simona; Kragelj Borut; Žumer-Pregelj Mirjana
Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach)
2000 ►
-
Čufer Tanja
Rak dojke
2000 ►
-
Čufer A; Močivnik M
r-Hu eritropoetin (r-Hu EPO), uporaba in učinki zdravljenja v našem centru
2000 ►
-
Kragelj Borut; Sedmak Boris; Červek Jožica; Čufer Tanja
Improving the quality of life of patients with TCC by sequential chemoradiotherapy
2000 ►
-
Čufer Tanja
2nd international symposyum on organ sparing treatment in oncology; 2000 Sep 14-16; Ljubljana: preface
2000 ►
-
Čufer Tanja
Internistična onkologija
2000 ►
-
Prechtl Anita; Thomssen Christoph; Meisner Christoph; Untch Michael; Weikel Werner; Wieland Gabriele; Lisboa Bjoern W; Hantschmann Peter; Beck Thomas; Čufer Tanja; et al ;
Risk-adapted adjuvant chemotherapy in node-negative breast cancer patients guided by prognostic factors uPA and PAl-1: first interim-analysis of a randomized trial
2000 ►
-
Therasse P; Mauriac L; Welnicka M; Bruning P; Čufer T; Lichinitser R; Pluzanska A; Tomiak E; Koopmanschap M; Piccart M
The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study: results of an EORTC-NCIC-SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)
1999 ►
-
Malik I; Roth A; Ghilezan N; Čufer T; Lazarev A; Doval D; Ionescu-Goga S; Chernozemsky I; Quinaux E; Chirina N
A phase II trial of taxotere (TXT) 100 or 75 mg/m2 as 2nd line chemotherapy (CT) in patients (PTS) with metastatic breast cancer (mbc) with stratification according to prognosis factors
1999 ►
-
Kozjek F; Sonc M; Čufer T; Primožič S
Drug-drug interactions and pseudo double medications in the treatment of oncological patients
1999 ►
-
Čufer Tanja
New developments in the adjuvant therapy of breast cancer
1999 ►
-
Čufer Tanja
Combined modality treatment with organ preservation in invasive bladder cancer
[Kombinirano zdravljenje raka sečnega mehurja z možnostjo ohranitve organa]
2000 ►
-
Bonnefoi H; Biganzoli L; Čufer T; Hamilton A; Mauriac L; Van Hoorebeeck I; Piccart M
A feasibility study of epirubicin (E) in combination with cyclophosphamide (C) and infusional 5-fluorouracil (F-infu)(CEF-infu) as primary treatment of large operable (LO) or locally advanced/inflammatory (LA/I) breast cancer (BC)
1999 ►
-
Čufer Tanja
Bomo pri zdravljenju raka sledili dokazom (evidence-based medicine) ali ugledu (eminence-based medicine)?
1999 ►
-
Zwitter M; Čufer T
Phase II trial of gemcitabine (Gem) and vincristine (Vin) for stage IV non small cell lung cancer (NSCLC)
1999 ►
-
Čufer Tanja
Uvod
1999 ►
-
Serša Gregor; Štabuc Borut; Čufer Tanja; Jančar Boris; Miklavčič Damijan; Čemažar Maja; Rudolf Zvonimir
Elektrokemoterapija malignega melanoma
[Electrochemotherapy of malignant melanoma]
1999 ►
-
Štabuc Borut; Čufer Tanja; Bergant Otmar; Kocijan Andrej; Primic-Žakelj Maja; Ulčar Metka
Rak pri moškem. 7. seminar "In memoriam dr. Dušana Reje"
1999 ►
-
Pajk Bojana; Čufer Tanja
Urgentna stanja v onkologiji
1999 ►
-
Čufer Tanja
Potek, prognoza in zdravljenje raka dojk
1998 ►
1 101 201 301 401 501
New search
Comments
Top of page
Institute for Biostatistics and Medical Informatics